Results 51 to 60 of about 72,644 (316)
Journal of Clinical Oncology, 2018 Purpose To provide evidence-based recommendations to practicing physicians and others on the management of malignant pleural mesothelioma. Methods ASCO convened an Expert Panel of medical oncology, thoracic surgery, radiation oncology, pulmonary ...
H. Kindler +13 more
semanticscholar +1 more source
Egyptian Journal of Chest Disease and Tuberculosis, 2014 Background: Malignant pleural mesothelioma (MPM) is a highly aggressive tumor that arises from the surface cells of the pleura with a poor survival rate.
Alaa eldin M. Elgazzar +4 more
doaj +1 more source
Pathologic diagnosis of malignant mesothelioma: chronological prospect and advent of recommendations and guidelines [PDF]
, 2015 Malignant mesothelioma is rare and difficult to diagnose. Its identification depends upon pathological investigation (cyto-histological assessment and immunohistochemistry) supported by clinical and radiological evidence.
Ascoli, Valeria
core +2 more sources
Nature Communications, 2019 Malignant pleural mesothelioma (MPM) is recognized as heterogeneous based both on histology and molecular profiling. Histology addresses inter-tumor and intra-tumor heterogeneity in MPM and describes three major types: epithelioid, sarcomatoid and ...
Y. Blum +19 more
semanticscholar +1 more source
Second line therapy in malignant pleural mesothelioma: a systematic review [PDF]
, 2015 After the implementation of standard first line chemotherapy with platinum and antifolates in pleural mesothelioma, patients are confronted with a need for second line treatment at relapse or progression.
Baas, Paul +3 more
core +2 more sources
Malignant pleural mesothelioma [PDF]
European Respiratory Journal, 1999 Malignant mesothelioma (MM) has recently attracted the attention of the media because of its relationship with professional and environmental exposure to asbestos. This tumour of the pleura is a disease which has emerged in significant numbers of patients during the last 30 years in the industrialized countries, and its increasing incidence makes it of
Frans A. N. Zoetmulder +3 more
openaire +2 more sources
In Vitro and in vivo anti-tumoral effects of the flavonoid apigenin in malignant mesothelioma [PDF]
, 2017 Malignant mesothelioma (MM) is a tumor arising from mesothelium. MM patients' survival is poor. The polyphenol 4',5,7,-trihydroxyflavone Apigenin (API) is a "multifunctional drug". Several studies have demonstrated API anti-tumoral effects.
Andrea Modesti +13 more
core +2 more sources
The development and characterization of a human mesothelioma in vitro 3D model to investigate immunotoxin therapy. [PDF]
, 2011 BackgroundTumor microenvironments present significant barriers to penetration by antibodies and immunoconjugates. Tumor microenvironments, however, are difficult to study in vitro.
Broaddus, V Courtney +8 more
core +3 more sources
Curcumin blocks autophagy and activates apoptosis of malignant mesothelioma cell lines and increases the survival of mice intraperitoneally transplanted with a malignant mesothelioma cell line [PDF]
, 2017 Malignant mesothelioma (MM) is a primary tumor arising from the serous membranes. The resistance of MM patients to conventional therapies, and the poor patients' survival, encouraged the identification of molecular targets for MM treatment. Curcumin (CUR)
Bei, Roberto +10 more
core +1 more source
The management of malignant pleural mesothelioma [PDF]
European Journal of Cardio-Thoracic Surgery, 2003 there was a local recurrence of the tumor 2 years after the last operation on the thorax (right upper lobe of the lung, right pulmonary hilum, and behind the sternum). Surgical resection was not indicated because a right pneumonectomy under permanent left phrenic paralysis would have been necessary for a complete resection. Concurrent chemoradiotherapy
MAGGI G. +3 more
openaire +3 more sources